title: Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats.
abstract: The proliferation of vascular smooth muscle cells (VSMCs) induced by injury to the intima of arteries is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis. Esculetin, derived from the Chinese herb Artemisia scoparia, is well known as a lipoxygenase inhibitor. We have investigated the inhibitory effects of esculetin on VSMC proliferation and intimal hyperplasia by balloon angioplasty in the rat. We determined, using [3H]thymidine incorporation and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, that esculetin inhibited the proliferation of VSMCs via a lipoxygenase-independent pathway. Three predominant signaling pathways were identified to be inhibited by esculetin: (a) the activation of p42/44 mitogen-activated protein kinase (MAPK) and the downstream effectors of c-fos and c-jun immediate early genes by means of western and reverse transcription-polymerase chain reaction (RT-PCR) analyses; (b) the activation of nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1), using the electrophoretic mobility shift assay; and (c) the activation of phosphoinositide 3-kinase (PI 3-kinase) and cell cycle progression, by western blot analysis and flow cytometric detection. Furthermore, esculetin also profoundly inhibited Ras activation, a shared upstream event of the above signaling cascades. In vascular injury studies, intraperitoneal administration of esculetin significantly suppressed intimal hyperplasia induced by balloon angioplasty. We conclude that esculetin blocks cell proliferation via the inhibition of an upstream effector of Ras and downstream events including p42/44 MAPK activation, PI 3-kinase activation, immediate early gene expression, as well as NF-kappaB and AP-1 activation. It also inhibits intimal hyperplasia after balloon vascular injury in the rat, indicating the therapeutic potential for treating restenosis after arterial injury.
authors.affiliation: Pharmacological Institute, College of Medicine, National Taiwan University, No. 1 Jen-Ai Road, Sect. 1, Taipei, Taiwan, ROC.
authors.forename: Shiow-Lin
authors.initials: SL
authors.lastname: Pan
authors.forename: Ying-Wen
authors.initials: YW
authors.lastname: Huang
authors.forename: Jih-Hwa
authors.initials: JH
authors.lastname: Guh
authors.forename: Ya-Ling
authors.initials: YL
authors.lastname: Chang
authors.forename: Chieh-Yu
authors.initials: CY
authors.lastname: Peng
authors.forename: Che-Ming
authors.initials: CM
authors.lastname: Teng
mesh_terms: D017130:Angioplasty; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D003251:Constriction, Pathologic / Q000517:prevention & control*; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D051381:Rats; D017208:Rats, Wistar; D055502:Secondary Prevention; D014468:Umbelliferones / Q000494:pharmacology / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000188:drug therapy*; D018631:ras Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D000975:Antioxidants; D014468:Umbelliferones; D018631:ras Proteins; C007628:esculetin